{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combined+Treatment&page=2", "query": { "intervention": "Combined Treatment", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 13936, "total_pages": 1394, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combined+Treatment&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combined+Treatment&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T21:36:54.800Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05436678", "title": "A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics" ], "interventions": [ { "name": "PrimeC 748 mg", "type": "DRUG" }, { "name": "Ciprofloxacin 750 MG", "type": "DRUG" }, { "name": "Celecoxib 200mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeuroSense Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 19, "start_date": "2022-07-26", "completion_date": "2022-10-20", "has_results": false, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-09-30T21:36:54.800Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05436678" }, { "nct_id": "NCT05722015", "title": "A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab Formulated with Berahyaluronidase Alfa", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Pegylated filgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 377, "start_date": "2023-02-14", "completion_date": "2028-05-22", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-30T21:36:54.800Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Clermont, Florida • Orange City, Florida + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Clermont", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Skokie", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05722015" }, { "nct_id": "NCT05949008", "title": "Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "NIDDM", "Obesity" ], "interventions": [ { "name": "Metformin Extended Release (ER) Oral Tablet", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2023-11-22", "completion_date": "2028-07-30", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-09-30T21:36:54.800Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05949008" }, { "nct_id": "NCT05061017", "title": "Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "Metastatic Colorectal Carcinoma", "Refractory Melanoma" ], "interventions": [ { "name": "Pixatimod", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cyclophosphamide (low dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diwakar Davar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-12-09", "completion_date": "2024-03-18", "has_results": true, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-30T21:36:54.800Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05061017" }, { "nct_id": "NCT06953089", "title": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "DB-1311/BNT324", "type": "DRUG" }, { "name": "BNT327", "type": "DRUG" }, { "name": "DB-1305/BNT325", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2025-07-18", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-30T21:36:54.800Z", "location_count": 15, "location_summary": "Los Angeles, California • Wheat Ridge, Colorado • Florida City, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Florida City", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06953089" }, { "nct_id": "NCT02801864", "title": "tDCS as an Adjuvant to Intensive Speech Therapy for Chronic Post Stroke Aphasia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aphasia", "Language" ], "interventions": [ { "name": "Real tDCS", "type": "DEVICE" }, { "name": "Sham tDCS", "type": "DEVICE" }, { "name": "Intensive Speech Therapy", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Austin Speech Labs", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "20 Years to 85 Years" }, "enrollment_count": 6, "start_date": "2016-01", "completion_date": "2019-06", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-30T21:36:54.800Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02801864" }, { "nct_id": "NCT00096993", "title": "A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 131, "start_date": "2005-01", "completion_date": "2007-09", "has_results": true, "last_update_posted_date": "2015-06-10", "last_synced_at": "2026-09-30T21:36:54.800Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096993" }, { "nct_id": "NCT00028314", "title": "Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Lipodystrophy", "Wasting Disease" ], "interventions": [ { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Atazanavir/Ritonavir", "type": "DRUG" }, { "name": "Lopinavir/Ritonavir", "type": "DRUG" }, { "name": "Nevirapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 150, "start_date": "2002-03", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2013-07-29", "last_synced_at": "2026-09-30T21:36:54.800Z", "location_count": 25, "location_summary": "Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028314" }, { "nct_id": "NCT04493138", "title": "Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic Syndrome", "Recurrent Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-07-21", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-30T21:36:54.800Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493138" }, { "nct_id": "NCT01809678", "title": "Yoga as a Complementary Therapy for Smoking Cessation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tobacco Dependence" ], "interventions": [ { "name": "Smoking Cessation", "type": "BEHAVIORAL" }, { "name": "Yoga", "type": "BEHAVIORAL" }, { "name": "Wellness", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "The Miriam Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 255, "start_date": "2012-07", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2021-07-19", "last_synced_at": "2026-09-30T21:36:54.800Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01809678" } ] }